US 12,134,658 B2
Materials and methods for multidirectional biotransportation in virotherapeutics
Rajkumar Ganesan, Blue Bell, PA (US); Adam Zwolak, Bala Cynwyd, PA (US); Ian White, Conshohocken, PA (US); Ninkka Tamot, Colmar, PA (US); Paul B. Harvilla, Nazareth, PA (US); Rajitha Doddareddy, Fort Washington, PA (US); Sanjaya Singh, Blue Bell, PA (US); and Martin Jack Borrok, III, Chalfont, PA (US)
Assigned to JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed by JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed on Aug. 2, 2021, as Appl. No. 17/391,744.
Claims priority of provisional application 63/222,332, filed on Jul. 15, 2021.
Claims priority of provisional application 63/145,883, filed on Feb. 4, 2021.
Claims priority of provisional application 63/145,896, filed on Feb. 4, 2021.
Claims priority of provisional application 63/145,877, filed on Feb. 4, 2021.
Claims priority of provisional application 63/145,893, filed on Feb. 4, 2021.
Claims priority of provisional application 63/145,875, filed on Feb. 4, 2021.
Claims priority of provisional application 63/145,888, filed on Feb. 4, 2021.
Claims priority of provisional application 63/145,887, filed on Feb. 4, 2021.
Claims priority of provisional application 63/145,876, filed on Feb. 4, 2021.
Claims priority of provisional application 63/145,880, filed on Feb. 4, 2021.
Claims priority of provisional application 63/145,873, filed on Feb. 4, 2021.
Claims priority of provisional application 63/145,890, filed on Feb. 4, 2021.
Claims priority of provisional application 63/075,687, filed on Sep. 8, 2020.
Claims priority of provisional application 63/075,673, filed on Sep. 8, 2020.
Claims priority of provisional application 63/075,647, filed on Sep. 8, 2020.
Claims priority of provisional application 63/075,664, filed on Sep. 8, 2020.
Claims priority of provisional application 63/075,677, filed on Sep. 8, 2020.
Claims priority of provisional application 63/075,580, filed on Sep. 8, 2020.
Claims priority of provisional application 63/075,606, filed on Sep. 8, 2020.
Claims priority of provisional application 63/075,539, filed on Sep. 8, 2020.
Claims priority of provisional application 63/075,628, filed on Sep. 8, 2020.
Claims priority of provisional application 63/075,568, filed on Sep. 8, 2020.
Claims priority of provisional application 63/075,504, filed on Sep. 8, 2020.
Claims priority of provisional application 63/060,552, filed on Aug. 3, 2020.
Claims priority of provisional application 63/060,372, filed on Aug. 3, 2020.
Claims priority of provisional application 63/060,385, filed on Aug. 3, 2020.
Claims priority of provisional application 63/060,307, filed on Aug. 3, 2020.
Claims priority of provisional application 63/060,409, filed on Aug. 3, 2020.
Claims priority of provisional application 63/060,354, filed on Aug. 3, 2020.
Claims priority of provisional application 63/060,435, filed on Aug. 3, 2020.
Claims priority of provisional application 63/060,293, filed on Aug. 3, 2020.
Claims priority of provisional application 63/060,421, filed on Aug. 3, 2020.
Claims priority of provisional application 63/060,359, filed on Aug. 3, 2020.
Claims priority of provisional application 63/060,444, filed on Aug. 3, 2020.
Prior Publication US 2022/0033522 A1, Feb. 3, 2022
Int. Cl. C07K 16/40 (2006.01); A61K 39/00 (2006.01); C07K 16/10 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/40 (2013.01) [C07K 16/10 (2013.01); C07K 16/283 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A multispecific molecule comprising: (a) a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR), and (b) a second binding domain that specifically binds to SARS-COV-2, wherein the first binding domain comprises a single-domain antibody (VHH) comprising:
(a) a CDR1 comprising the amino acid sequence of SEQ ID NO:1, a CDR2 comprising the amino acid sequence of SEQ ID NO:2, and a CDR3 comprising the amino acid sequence of SEQ ID NO:3;
(b) a CDR1 comprising the amino acid sequence of SEQ ID NO:4, a CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a CDR3 comprising the amino acid sequence of SEQ ID NO:6;
(c) a CDR1 comprising the amino acid sequence of SEQ ID NO:7, a CDR2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR3 comprising the amino acid sequence of SEQ ID NO:9;
(d) a CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a CDR3 comprising the amino acid sequence of SEQ ID NO:12;
(e) a CDR1 comprising the amino acid sequence of SEQ ID NO:13, a CDR2 comprising the amino acid sequence of SEQ ID NO:14, and a CDR3 comprising the amino acid sequence of SEQ ID NO:15;
(f) a CDR1 comprising the amino acid sequence of SEQ ID NO:17, a CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and a CDR3 comprising the amino acid sequence of SEQ ID NO:19;
(g) a CDR1 comprising the amino acid sequence of SEQ ID NO:20, a CDR2 comprising the amino acid sequence of SEQ ID NO:21, and a CDR3 comprising the amino acid sequence of SEQ ID NO:22;
(h) a CDR1 comprising the amino acid sequence of SEQ ID NO:23, a CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a CDR3 comprising the amino acid sequence of SEQ ID NO:25;
(i) a CDR1 comprising the amino acid sequence of SEQ ID NO:26, a CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a CDR3 comprising the amino acid sequence of SEQ ID NO:28; or
(j) a CDR1 comprising the amino acid sequence of SEQ ID NO:29, a CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a CDR3 comprising the amino acid sequence of SEQ ID NO:31;
and wherein the second binding domain comprises a peptide comprising:
(a) angiotensin-converting enzyme 2 (ACE2);
comprising the amino acid sequence of SEQ ID NO: 194;
(b) the extracellular domain of ACE2;
comprising the amino acid sequence of SEQ ID NO: 134; or
(c) a truncated extracellular domain of ACE2;
comprising the amino acid sequence of SEQ ID NO: 120 or the amino acid sequence of SEQ ID NO: 121.